Please assess the completion status of the following clinical trial:

Trial Title: TH9507 in Patients With HIV-Associated Lipodystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 65 years inclusive~* HIV positive; CD4 cell counts \>100 cells/mm3; viral load \<10,000 copies/mL (stable for 8 weeks)~* On stable ART regimen for at least 8 weeks prior to randomization~* Have evidence of abdominal fat accumulation defined by the following anthropometric cut off values:~  * For males: waist circumference \> 95 cm and waist to hip ratio \> 0.94;~ * For females: waist circumference \> 94 cm and waist to hip ratio \> 0.88.~* Females of childbearing potential not pregnant or lactating; normal mammography within 6 months of study.~* Signed informed consent~Exclusion Criteria:~* Body mass index \< 20 kg/m2~* Opportunistic infection; HIV-related disease within 3 months of study.~* History of malignancy; active neoplasm.~* Prostate-specific antigen (PSA) \>5 ng/mL at screening~* Hypopituitarism; history of pituitary tumor/surgery; head irradiation; head trauma that has affected the somatotropic axis.~* Untreated hypothyroidism~* Type 1 diabetics and type 2 diabetics on oral hypoglycemic or insulin sensitizing agent within 6 months of study~* ALT or AST \> 3 x ULN; serum creatinine \> 133 mmol/L (1.5 mg/dL); hemoglobin more than 20 g/L below LLN; fasting blood glucose \> 8.33 mmol/L (150 mg/dL); fasting triglycerides \> 11.3 mmol/L (0.99 g/dL).~* Untreated hypertension~* Change in anti-hyperlipemic regimen within 3 months prior to study~* Change in testosterone regimen and/or supraphysiological dose of testosterone~* Estrogen therapy~* Anoretics/anorexigenics or anti-obesity agents within 3 months of study~* Growth hormone (GH); GH secretagogues; growth hormone releasing factor (GRF) products; IGF-1; or IGFBP-3 within 6 months of study.~* Drug or alcohol dependence or use of methadone within 6 months of study entry~* Participation in a clinical trial with any investigational drug/device within 30 days of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).